research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:44:15 ON 06 DEC 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 18:44:28 ON 06 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 DEC 2006 HIGHEST RN 914910-45-5
DICTIONARY FILE UPDATES: 5 DEC 2006 HIGHEST RN 914910-45-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10729837.str



chain nodes :
16 17 27 28 29
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 18 19 20 21 22 23 24 25 26

```
chain bonds :
2-11  14-16  16-17  17-18  19-28  24-29  25-27
ring bonds :
1-2  1-5  1-9  2-3  3-4  4-5  5-6  6-7  7-8  8-9  10-11  10-15  11-12  12-13  13-14
 14-15  18-19  18-23  19-20  20-21  21-22  21-24  22-23  22-26  24-25  25-26
exact/norm bonds :
1-2  2-3  2-11  3-4  4-5  10-11  10-15  11-12  12-13  13-14  14-15  14-16  21-24
22-26  24-25  25-26  25-27
exact bonds :
16-17  17-18  19-28  24-29
normalized bonds :
1-5  1-9  5-6  6-7  7-8  8-9  18-19  18-23  19-20  20-21  21-22  22-23


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:CLASS  17:CLASS  18:Atom  19:Atom
20:Atom  21:Atom  22:Atom  23:Atom  24:Atom  25:Atom  26:Atom  27:CLASS  28:CLASS
29:CLASS



L1      STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1              STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.


=> s l1 full
FULL SEARCH INITIATED 18:46:23 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      141 TO ITERATE

100.0% PROCESSED      141 ITERATIONS                                  46 ANSWERS
SEARCH TIME: 00.00.01

L2           46 SEA SSS FUL L1

=> d l2 1-10
```

L2 ANSWER 1 OF 46 REGISTRY COPYRIGHT 2006 ACS on STN
RN 913329-18-7 REGISTRY
ED Entered STN: 16 Nov 2006
CN Imidodicarbonimidic diamide, N,N-dimethyl-, monohydrochloride, mixt. with 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one (9CI) (CA INDEX NAME)
MF C21 H21 Cl N4 O S . C4 H11 N5 . Cl H
CI MXS
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S



CM 2

CRN 1115-70-4 (657-24-9)
CMF C4 H11 N5 . Cl H



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 2 OF 46 REGISTRY COPYRIGHT 2006 ACS on STN
RN 909419-73-4 REGISTRY
ED Entered STN: 03 Oct 2006
CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, compd. with 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one (1:1) (9CI) (CA INDEX NAME)
MF C21 H21 Cl N4 O S . C10 H16 O4 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S



CM 2

CRN 5872-08-2
CMF C10 H16 O4 S



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 3 OF 46 REGISTRY COPYRIGHT 2006 ACS on STN
RN 909419-72-3 REGISTRY
ED Entered STN: 03 Oct 2006
CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (1R,4S)-, compd. with 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H21 Cl N4 O S . C10 H16 O4 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S



CM 2

CRN 35963-20-3
CMF C10 H16 O4 S

Absolute stereochemistry. Rotation (-).



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 4 OF 46 REGISTRY COPYRIGHT 2006 ACS on STN
RN 909419-71-2 REGISTRY
ED Entered STN: 03 Oct 2006
CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (1S,4R)-, compd. with 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H21 Cl N4 O S . C10 H16 O4 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S



CM 2

CRN 3144-16-9
CMF C10 H16 O4 S

Absolute stereochemistry. Rotation (+).



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 5 OF 46 REGISTRY COPYRIGHT 2006 ACS on STN
RN 909419-70-1 REGISTRY
ED Entered STN: 03 Oct 2006
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monohydrate (9CI) (CA INDEX NAME)
MF C21 H21 Cl N4 O S . H2 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (146939-27-7)



● H_2O

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 6 OF 46 REGISTRY COPYRIGHT 2006 ACS on STN
RN 909389-56-6 REGISTRY
ED Entered STN: 03 Oct 2006
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, diacetate (9CI) (CA INDEX NAME)
MF C21 H21 Cl N4 O S . 2 C2 H4 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S



CM 2

CRN 64-19-7
CMF C2 H4 O2

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 7 OF 46 REGISTRY COPYRIGHT 2006 ACS on STN
RN 909389-55-5 REGISTRY
ED Entered STN: 03 Oct 2006
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, hydrobromide (5:8) (9CI) (CA INDEX NAME)
MF C21 H21 Cl N4 O S . 8/5 Br H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (146939-27-7)



●8/5 HBr

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 8 OF 46 REGISTRY COPYRIGHT 2006 ACS on STN
RN 884305-08-2 REGISTRY
ED Entered STN: 15 May 2006
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-1-hydroxyethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)
MF C21 H21 Cl N4 O2 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 9 OF 46 REGISTRY COPYRIGHT 2006 ACS on STN
RN 884305-07-1 REGISTRY
ED Entered STN: 15 May 2006
CN 2H-Indol-2-one, 5-[[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]acetyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)
MF C21 H19 Cl N4 O2 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 10 OF 46 REGISTRY COPYRIGHT 2006 ACS on STN
RN 881169-56-8 REGISTRY
ED Entered STN: 20 Apr 2006
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monohydrobromide (9CI) (CA INDEX NAME)
MF C21 H21 Cl N4 O S . Br H
SR CA
LC STN Files: CA, CAPLUS
CRN (146939-27-7)



● HBr

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>
Uploading C:\Program Files\Stnexp\Queries\10729837a.str



chain nodes :
16 17 27 28 29
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 18 19 20 21 22 23 24 25
26
chain bonds :
2-11 14-16 16-17 17-18 19-28 24-29 25-27
ring bonds :
1-2 1-5 1-9 2-3 3-4 4-5 5-6 6-7 7-8 8-9 10-11 10-15 11-12 12-13 13-14
14-15 18-19 18-23 19-20 20-21 21-22 21-24 22-23 22-26 24-25 25-26
exact/norm bonds :
1-2 2-3 2-11 3-4 4-5 10-11 10-15 11-12 12-13 13-14 14-15 21-24 22-26
24-25 25-26 25-27
exact bonds :
14-16 16-17 17-18 19-28 24-29
normalized bonds :
1-5 1-9 5-6 6-7 7-8 8-9 18-19 18-23 19-20 20-21 21-22 22-23

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:CLASS 28:CLASS
29:CLASS

L3 STRUCTURE UPLOADED

=> d
L3 HAS NO ANSWERS
L3 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

```
=> d l3
L3 HAS NO ANSWERS
L3              STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.


=> s l3 full
FULL SEARCH INITIATED 18:49:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      141 TO ITERATE

100.0% PROCESSED      141 ITERATIONS                          44 ANSWERS
SEARCH TIME: 00.00.01

L4            44 SEA SSS FUL L3

=> d l4 1-10
```

L4 ANSWER 1 OF 44 REGISTRY COPYRIGHT 2006 ACS on STN
RN 913329-18-7 REGISTRY
ED Entered STN: 16 Nov 2006
CN Imidodicarbonimidic diamide, N,N-dimethyl-, monohydrochloride, mixt. with 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one (9CI) (CA INDEX NAME)
MF C21 H21 Cl N4 O S . C4 H11 N5 . Cl H
CI MXS
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S



CM 2

CRN 1115-70-4 (657-24-9)
CMF C4 H11 N5 . Cl H



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 2 OF 44 REGISTRY COPYRIGHT 2006 ACS on STN
RN 909419-73-4 REGISTRY
ED Entered STN: 03 Oct 2006
CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, compd. with 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one (1:1) (9CI) (CA INDEX NAME)
MF C21 H21 Cl N4 O S . C10 H16 O4 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S



CM 2

CRN 5872-08-2
CMF C10 H16 O4 S



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 3 OF 44 REGISTRY COPYRIGHT 2006 ACS on STN
RN 909419-72-3 REGISTRY
ED Entered STN: 03 Oct 2006
CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (1R,4S)-, compd. with 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H21 Cl N4 O S . C10 H16 O4 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S



CM 2

CRN 35963-20-3
CMF C10 H16 O4 S

Absolute stereochemistry. Rotation (-).



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 4 OF 44 REGISTRY COPYRIGHT 2006 ACS on STN
RN 909419-71-2 REGISTRY
ED Entered STN: 03 Oct 2006
CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (1S,4R)-, compd. with 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H21 Cl N4 O S . C10 H16 O4 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S



CM 2

CRN 3144-16-9
CMF C10 H16 O4 S

Absolute stereochemistry. Rotation (+).



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 5 OF 44 REGISTRY COPYRIGHT 2006 ACS on STN
RN 909419-70-1 REGISTRY
ED Entered STN: 03 Oct 2006
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monohydrate (9CI) (CA INDEX NAME)
MF C21 H21 Cl N4 O S . H2 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (146939-27-7)



● H_2O

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 6 OF 44 REGISTRY COPYRIGHT 2006 ACS on STN
RN 909389-56-6 REGISTRY
ED Entered STN: 03 Oct 2006
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, diacetate (9CI) (CA INDEX NAME)
MF C21 H21 Cl N4 O S . 2 C2 H4 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S



CM 2

CRN 64-19-7
CMF C2 H4 O2

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 7 OF 44 REGISTRY COPYRIGHT 2006 ACS on STN
RN 909389-55-5 REGISTRY
ED Entered STN: 03 Oct 2006
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, hydrobromide (5:8) (9CI) (CA INDEX NAME)
MF C21 H21 Cl N4 O S . 8/5 Br H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (146939-27-7)



●8/5 HBr

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 8 OF 44 REGISTRY COPYRIGHT 2006 ACS on STN
RN 881169-56-8 REGISTRY
ED Entered STN: 20 Apr 2006
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monohydrobromide (9CI) (CA INDEX NAME)
MF C21 H21 Cl N4 O S . Br H
SR CA
LC STN Files: CA, CAPLUS
CRN (146939-27-7)



● HBr

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 9 OF 44 REGISTRY COPYRIGHT 2006 ACS on STN
RN 881169-53-5 REGISTRY
ED Entered STN: 20 Apr 2006
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H21 Cl N4 O S . C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 10 OF 44 REGISTRY COPYRIGHT 2006 ACS on STN
RN 881169-52-4 REGISTRY
ED Entered STN: 20 Apr 2006
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monoacetate (9CI) (CA INDEX NAME)
MF C21 H21 Cl N4 O S . C2 H4 O2
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S



CM 2

CRN 64-19-7
CMF C2 H4 O2

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> FIL REGISTRY

=> SET TERMSET E#

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	386.40	386.61

FILE 'REGISTRY' ENTERED AT 19:05:38 ON 06 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 DEC 2006 HIGHEST RN 914910-45-5
DICTIONARY FILE UPDATES: 5 DEC 2006 HIGHEST RN 914910-45-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> DEL SEL Y

SET COMMAND COMPLETED

=> SEL L4 1 RN

=> S E1/RN

E1 THROUGH E1 ASSIGNED

=> SET TERMSET LOGIN

SET COMMAND COMPLETED

=> FIL CAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.52	387.13

FILE 'CAPLUS' ENTERED AT 19:05:40 ON 06 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 6 Dec 2006 VOL 145 ISS 24
FILE LAST UPDATED: 5 Dec 2006 (20061205/ED)


```
=>  S L4

L5          594 L4

=>
=> s l5 and amorph?
         268712 AMORPH?
L6            14 L5 AND AMORPH?

=> d l6 1-14 ibib abs hitstr
```

L6 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:818149 CAPLUS
DOCUMENT NUMBER: 145:230653
TITLE: Drying process for the preparation of amorphous ziprasidone mesylate from ziprasidone mesylate dihydrate
INVENTOR(S): Aronhime, Judith; Mendelovici, Marioara; Levi, Sigalit; Mainfeld, Alex; Gold, Amir
PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals Usa, Inc.
SOURCE: PCT Int. Appl., 19pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006086779	A1	20060817	WO 2006-US5114	20060213

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-652356P P 20050211

AB A drying process for the preparation of amorphous ziprasidone mesylate from ziprasidone mesylate dihydrate is presented and pharmaceutical compns. containing amorphous ziprasidone mesylate are claimed.

IT 199191-70-3
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); RCT (Reactant); PROC (Process); RACT (Reactant or reagent)
(drying process for the preparation of amorphous ziprasidone mesylate from ziprasidone mesylate dihydrate)

RN 199191-70-3 CAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monomethanesulfonate, dihydrate (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S

L6 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 75-75-2
CMF C H4 O3 S

IT 185021-64-1P, Ziprasidone mesylate
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drying process for the preparation of amorphous ziprasidone mesylate from ziprasidone mesylate dihydrate)

RN 185021-64-1 CAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S

L6 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 75-75-2
CMF C H4 O3 S

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:817950 CAPLUS
DOCUMENT NUMBER: 145:235744
TITLE: Process of preparing ziprasidone mesylate
INVENTOR(S): Mainfeld, Alex; Gold, Amir; Mendelovici, Marioara
PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals Usa, Inc.
SOURCE: PCT Int. Appl., 24pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006086787	A1	20060817	WO 2006-US5188	20060213

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2006258679	A1	20061116	US 2006-353304	20060213
PRIORITY APPLN. INFO.:			US 2005-652294P	P 20050211
			US 2005-652356P	P 20050211
			US 2005-661687P	P 20050314
			US 2005-689701P	P 20050609
			US 2005-705762P	P 20050804
			US 2006-762349P	P 20060125
			US 2006-762695P	P 20060126

AB In one embodiment, the present invention provides a process of preparing amorphous ziprasidone mesylate comprising the step of spray-drying a solution of ziprasidone mesylate in a solvent selected from a group consisting of: C1-C5 alcs., C2-C8 ethers, glacial acetic acid and mixts. thereof with water, using an outlet temperature of above about 90° Preferably the inlet temperature is above the outlet temperature In another embodiment, the present invention provides a process of preparing ziprasidone mesylate crystal form characterized by x-ray powder diffraction peaks at 11.7, 17.3, 23.5, 24.2, and 25.2 degrees two-theta, ± 0.2 degrees two-theta (herein defined as Form I) comprising the step of spray-drying a solution of ziprasidone mesylate in a solvent selected from a group consisting of: glacial acetic acid and mixts. thereof with C2-C8 ethers using an outlet temperature of above about 70 °C, and collecting the obtained Form I. Preferably the inlet temperature is above the outlet temperature In another embodiment, the present invention provides a process of preparing ziprasidone mesylate crystal form characterized by x-ray powder diffraction peaks at 17.1, 18.7, 23.8, and 24.4 degrees two-theta, ±0.2 degrees two-theta (herein defined as Form VIII) comprising the step of spray-drying a solution of ziprasidone mesylate in C1-C5 alcs. and mixts. thereof with water using an outlet temperature of from about above 45 c°C to about 70 °C. Preferably the inlet temperature is above the outlet temperature For example, wet ziprasidone mesylate dihydrate needle crystals 3.8

L6 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
g were dissolved in ethanol 80 mL and water 20 mL. The ziprasidone mesylate soln. was sprayed at a spray vol. of 440 mL/h into a chamber contg. a parallel flow of nitrogen heated to about 150 °C (flow rate of about 38 m3/h). The outlet temp. was maintained at about 90°. A fraction was collected and detd. to be amorphous ziprasidone mesylate, XRD.

IT 185021-64-1P, Ziprasidone mesylate
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(process of preparing ziprasidone mesylate)

RN 185021-64-1 CAPLUS

CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S



CM 2

CRN 75-75-2
CMF C H4 O3 S

IT 199191-70-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(process of preparing ziprasidone mesylate)

RN 199191-70-3 CAPLUS

CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monomethanesulfonate, dihydrate (9CI) (CA INDEX

L6 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
NAME)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S



CM 2

CRN 75-75-2
CMF C H4 O3 S

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1288708 CAPLUS
DOCUMENT NUMBER: 144:40787
TITLE: Pharmaceutical compositions with enhanced performance containing hydroxypropyl methyl cellulose derivatives
INVENTOR(S): Babcock, Walter Christian; Friesen, Dwayne Thomas; Lyon, David Keith; Miller, Warren Kenyon; Smithey, Daniel Tod
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005115330	A2	20051208	WO 2005-IB1580	20050518
WO 2005115330	A3	20060706		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-575541P P 20040528
US 2004-586549P P 20040709

AB Disclosed are hydroxypropyl Me cellulose acetate succinate (HPMCAS) and hydroxypropyl Me cellulose acetate with unique degrees of substitution of hydroxypropoxy, methoxy, acetyl, and succinoyl groups. When used in making compns. comprising a low-solubility drug and such polymers, the polymers provide enhanced aqueous concns. and/or improved phys. stability. A solid amorphous dispersion of 50% torcetrapib in 50% HPMCAS with varying degrees of substitution groups was prepared and spry dried. The in vivo release of the drugs in dogs showed that the composition provided enhanced drug concentration and relative bioavailability relative to the amorphous drug.

IT 146939-27-7
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. with enhanced performance containing hydroxypropyl Me cellulose derivs.)

RN 146939-27-7 CAPLUS

CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L6 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1224322 CAPLUS
DOCUMENT NUMBER: 143:483095
TITLE: Preparation of amorphous ziprasidone hydrochloride
INVENTOR(S): Zetina-Rocha, Carlos; Rey, Allan W.; Buck, Matthew A.; Derdour, Lotfi; Horne, Stephen E.; Murthy, Keshava K. S.
PATENT ASSIGNEE(S): Apotex Pharmachem Inc., Can.
SOURCE: U.S. Pat. Appl. Publ., 6 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005256139	A1	20051117	US 2004-884991	20040707
CA 2467538	AA	20051114	CA 2004-2467538	20040514
WO 2005111032	A1	20051124	WO 2004-CA981	20040707
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: CA 2004-2467538 A 20040514
GI



I

AB The present invention relates to a new and useful amorphous form of ziprasidone hydrochloride (I). I amorphous form was prepared by treatment of the base in heptanes with HCl gas.
IT 122883-93-6P, Ziprasidone hydrochloride
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amorphous ziprasidone hydrochloride)
RN 122883-93-6 CAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-

L6 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
chloro-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



IT 146939-27-7, Ziprasidone
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of amorphous ziprasidone hydrochloride)
RN 146939-27-7 CAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



L6 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1154548 CAPLUS
DOCUMENT NUMBER: 143:427349
TITLE: Preparation of amorphous ziprasidone hydrochloride
INVENTOR(S): Tyagi, Om Dutt; Srivastava, Tushar Kumar; Chavan, Yuvraj Atmaram
PATENT ASSIGNEE(S): Lupin Limited, India
SOURCE: PCT Int. Appl., 10 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005100348	A1	20051027	WO 2005-IN115	20050415
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: IN 2004-MU450 A 20040415
GI



I

AB A process for preparation of ziprasidone hydrochloride (I) which is in amorphous form. The process comprises providing a I solution in a mixture of alc. solvent and acetonitrile and spray drying the solution of I.
IT 122883-93-6, Ziprasidone hydrochloride
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(preparation of amorphous ziprasidone hydrochloride)
RN 122883-93-6 CAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:638706 CAPLUS
DOCUMENT NUMBER: 143:159548
TITLE: Donepezil formulations
INVENTOR(S): Boehm, Garth; Dundon, Josephine
PATENT ASSIGNEE(S): Alpharma, Inc., USA
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005065645	A2	20050721	WO 2004-US42999	20041223
WO 2005065645	A3	20051027		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2552221	AA	20050721	CA 2004-2552221	20041223
US 2005232990	A1	20051020	US 2004-22346	20041223
PRIORITY APPLN. INFO.:			US 2003-533496P P	20031231
			WO 2004-US42999 W	20041223

AB Donepezil formulations, including amorphous donepezil or pharmaceutically acceptable salts thereof; sustained-release formulations; and donepezil sprinkle formulations are disclosed.
IT 146939-27-7, Ziprasidone
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(donepezil formulations)
RN 146939-27-7 CAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)

L6 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L6 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:493702 CAPLUS
DOCUMENT NUMBER: 141:54361
TITLE: Polymorphic forms of ziprasidone and its hydrochloride
INVENTOR(S): Reddy, Manne Satyanarayana; Srinivasan, Thirumalai Rajan; Uppala, Venka Bhaskara Rao; Venkatesh, Mummadi; Prabhakar, Akundi Surya
PATENT ASSIGNEE(S): Reddy's Laboratories Limited, India; Reddy's Laboratories Inc.
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050655	A1	20040617	WO 2003-US38489	20031204
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003300814	A1	20040623	AU 2003-300814	20031204
US 2004152711	A1	20040805	US 2003-729837	20031204
PRIORITY APPLN. INFO.:			IN 2002-MA907 A	20021204
			WO 2003-US38489 W	20031204

AB The present invention is related to crystalline forms of ziprasidone and its hydrochloride salt and an amorphous form of ziprasidone hydrochloride and the process for the preparation thereof. The crystalline forms and amorphous form of the invention are suitable for pharmaceutical purposes in the treatment of psychosis. The processes of the invention are simple, non-hazardous and com. suitable. Thus, 50 g 5-(2-chloroethyl)-6-chlorooxindole, 47.5 g 3-(1-piperazinyl)-1,2-benzisothiazole and 500 mL cyclohexane were charged into an autoclave, followed by adding sodium carbonate 46, sodium iodide 3.2, and tetrabutylphosphonium bromide 14.8 g and the reaction mixture was maintained at 95-102° and 2.5 kg/cm2 till the reaction was completed, cooled to 300°, treated with 250 mL H2O, filtered to give, after washing with 100 mL water, the wet compound The wet compound was suspended in water, filtered, washed water, resuspended in acetone, filtered, washed with acetone, filtered, and dried at 60-65° to give 65.7 g ziprasidone base. Ziprasidone (5 g) and 50 mL acetic acid were placed into a round bottom flask and heated to 45-50°, treated slowly with 25 mL aqueous HCl over 20 min, refluxed, and treated with 10 mL water, followed by addition of 50 mL isopropanol. The reaction mass was cooled to 50°, followed by distilling off the solvent completely under vacuum., to give amorphous form of ziprasidone hydrochloride.
IT 146939-27-7P, Ziprasidone
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L6 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(X-ray diffraction anal.; prepn. of polymorphic forms of ziprasidone and its hydrochloride)
RN 146939-27-7 CAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



IT 122883-93-6P, Ziprasidone hydrochloride
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of polymorphic forms of ziprasidone and its hydrochloride)
RN 122883-93-6 CAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L6 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:142933 CAPLUS
DOCUMENT NUMBER: 140:187358
TITLE: Pharmaceutical compositions of semi-ordered drugs and polymers
INVENTOR(S): Babcock, Walter Christian; Caldwell, William Brett; Crew, Marshall David; Friesen, Dwayne Thomas; Smithey, Daniel Tod; Shanker, Ravi Mysore
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014342	A1	20040219	WO 2003-IB3465	20030731
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2496441	AA	20040219	CA 2003-2496441	20030731
AU 2003249474	A1	20040225	AU 2003-249474	20030731
EP 1530457	A1	20050518	EP 2003-784384	20030731
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003013428	A	20050628	BR 2003-13428	20030731
CN 1681479	A	20051012	CN 2003-821348	20030731
JP 2006500349	T2	20060105	JP 2004-527196	20030731
US 2004156905	A1	20040812	US 2003-636834	20030805
NO 2005000419	A	20050404	NO 2005-419	20050125

PRIORITY APPLN. INFO.: US 2002-403087P P 20020812
WO 2003-IB3465 W 20030731

AB A solid composition of a low-solubility drug and a concentration-enhancing polymer has a portion of the drug in a semi-ordered state. A dispersion contained (+)-N-{3-[3-(4-fluorophenoxy)phenyl]-2-cyclopenten-1-yl}-N-hydroxyurea (I) 0.25, HPMC 0.25, acetone 49.75, and methanol 49.75%, was spray-dried. The resulting solid amorphous spray-dried dispersion was collected, dried under vacuum, and stored in a desiccator. The solid amorphous dispersion was in the form of small particles having an average diameter of about 1.5 pm, but with a broad distribution of particle sizes. After drying, the solid amorphous dispersion contained 50 wt% I . The glass transition temperature of this spray-dried dispersion as a function of relative humidity was determined

IT 146939-27-7, Ziprasidone
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. of semi-ordered drugs and polymers)

RN 146939-27-7 CAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)

L6 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:610236 CAPLUS
DOCUMENT NUMBER: 139:154927
TITLE: Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
INVENTOR(S): Perlman, Michael Ellis; Shanker, Ravi Mysore; Babcock, Walter Christian; Friesen, Dwayne Thomas; Rabenstein, Mark David; Smithey, Daniel Tod
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003063833	A1	20030807	WO 2003-IB335	20030128
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2474838	AA	20030807	CA 2003-2474838	20030128
EP 1469832	A1	20041027	EP 2003-700435	20030128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003007344	A	20041214	BR 2003-7344	20030128
JP 2005523262	T2	20050804	JP 2003-563527	20030128
US 2003228358	A1	20031211	US 2003-355747	20030131

PRIORITY APPLN. INFO.: US 2002-354081P P 20020201
WO 2003-IB335 W 20030128

AB A pharmaceutical composition comprises a solid amorphous dispersion comprising a low-solubility drug and a concentration-enhancing polymer and a lipophilic microphase-forming material. Alternatively, a solid amorphous dispersion comprising a low-solubility drug and a concentration-enhancing polymer is co-administered with a lipophilic microphase-forming material to an in vivo use environment. A spray solution was formed containing 2.5 wt% drug, 7.5 wt% HPMCAS-MF, and 90% acetone. The solution was spray-dried by directing a 2-fluid external-mix spray nozzle at 2.7 bar with a feed rate of 190 g/min into the stainless-steel chamber of a spray-dryer, by using nitrogen as the drying gas, maintained at a temperature of 137° at the inlet; the drying gas and evaporated solvent exited the drier at 49°. The resulting solid amorphous dispersion was collected and then dried in a solvent tray-drier by spreading the spray-dried particles onto polyethylene-lined trays to a depth of not more than 1 cm and then drying them at 40° for 25 h. After drying, dispersion 1 contained 25 wt% drug.

IT 122883-93-6, Ziprasidone hydrochloride 146939-27-7, Ziprasidone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. of amorphous dispersions of drugs and lipophilic microphase-forming materials)

L6 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 122883-93-6 CAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



RN 146939-27-7 CAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:5811 CAPLUS
DOCUMENT NUMBER: 138:78458
TITLE: Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
INVENTOR(S): Babcock, Walter Christian; Curatolo, William John; Friesen, Dwayne Thomas; Ketner, Rodney James; Lo, Julian Belknap; Nightingale, James Alan Schriver; Shanker, Ravi Mysore; West, James Blair
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 212 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000294	A1	20030103	WO 2002-IB1800	20020513
WO 2003000294	C1	20031106		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2448864	AA	20030103	CA 2002-2448864	20020513
AU 2002304387	A1	20030108	AU 2002-304387	20020513
EP 1401503	A1	20040331	EP 2002-733019	20020513
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002010520	A	20040622	BR 2002-10520	20020513
JP 2005500313	T2	20050106	JP 2003-506936	20020513
US 2003104063	A1	20030605	US 2002-175640	20020619
PRIORITY APPLN. INFO.:			US 2001-300261P P	20010622
			WO 2002-IB1800 W	20020513

AB A pharmaceutical composition comprises a dispersion containing a low-solubility drug and a matrix combined with a concentration-enhancing polymer. At least a major portion of the drug is amorphous in the dispersion. The compns. improve the stability of the drug in the dispersion, and/or the concentration of drug in a use environment. For example, a solid drug/matrix dispersion comprised of 10% 3,5-dimethyl-4-(3'-pentoxy)-2-(2',4',6'-trimethylphenoxy)pyridine and 90% polyethylene glycol was prepared by a melt-congeal process. The solid drug/matrix dispersion was then combined with the concentration-enhancing polymer hydroxypropyl Me cellulose acetate succinate (HPMCAS). Addition of HPMCAS increased maximum concentration of drug in solution during the first 90 min (Cmax90) and the area under the aqueous concentration vs. time curve after 90 min (AUC90) by 1.12-fold and 1.19-fold, resp., compared to the solid drug/matrix dispersion with no concentration-enhancing polymer and by 2.38-fold and 2.25-fold, resp., compared to pure drug.
IT 185021-64-1

L6 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. contg. poorly-sol. drug/matrix solid dispersion and soly.-enhancing polymer)
RN 185021-64-1 CAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S



CM 2

CRN 75-75-2
CMF C H4 O3 S



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:5760 CAPLUS
DOCUMENT NUMBER: 138:78451
TITLE: Pharmaceutical compositions of adsorbates of amorphous drug
INVENTOR(S): Babcock, Walter Christian; Friesen, Dwayne Thomas; Shanker, Ravi Mysore; Smithey, Daniel Tod; Tadday, Ralph
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 218 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000238	A1	20030103	WO 2002-IB1792	20020521
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2448825	AA	20030103	CA 2002-2448825	20020521
EP 1404302	A1	20040407	EP 2002-730596	20020521
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200400034	A	20040615	EE 2004-34	20020521
BR 2002010519	A	20040622	BR 2002-10519	20020521
CN 1523979	A	20040825	CN 2002-812503	20020521
HU 200400281	A2	20040830	HU 2004-281	20020521
JP 2005501820	T2	20050120	JP 2003-506885	20020521
NZ 529490	A	20050826	NZ 2002-529490	20020521
US 2003054037	A1	20030320	US 2002-173987	20020617
ZA 2003008735	A	20040915	ZA 2003-8735	20031110
BG 108489	A	20040730	BG 2003-108489	20031222
PRIORITY APPLN. INFO.:			US 2001-300260P P	20010622
			WO 2002-IB1792 W	20020521

AB Pharmaceutical compns. comprise a low-solubility drug adsorbed onto a high surface area substrate to form an adsorbate. The compns. in some embodiments include a concentration-enhancing polymer. A drug/substrate adsorbate comprising quinoxaline-2-carboxylic acid[4(R)-carbamoyl-1(S)-3-fluorobenzyl-2(S), 7-dihydroxy-7-methyl-octyl]amide 10, and zinc oxide 90% (the substrate) was prepared. The Cmax,90 provided by the above adsorbate was 3.3-fold that of the crystalline control, while the AUC90 was 2.6-fold that of the control.
IT 185021-64-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. of adsorbates of amorphous drug)
RN 185021-64-1 CAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7

L6 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CMF C21 H21 Cl N4 O S



CM 2

CRN 75-75-2
CMF C H4 O3 S

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:5750 CAPLUS
DOCUMENT NUMBER: 138:78446
TITLE: Pharmaceutical compositions containing polymer and drug assemblies
INVENTOR(S): Babcock, Walter Christian; Crew, Marshall David; Friesen, Dwayne Thomas; Rabenstein, Mark David; Smithey, Daniel Tod; Shanker, Ravi Mysore
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 257 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000226	A2	20030103	WO 2002-IB2256	20020617
WO 2003000226	A3	20031023		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2450748	AA	20030103	CA 2002-2450748	20020617
AU 2002309172	A1	20030108	AU 2002-309172	20020617
US 2003170309	A1	20030911	US 2002-173945	20020617
EP 1401399	A2	20040331	EP 2002-735849	20020617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002011028	A	20040615	BR 2002-11028	20020617
JP 2004534811	T2	20041118	JP 2003-506873	20020617
PRIORITY APPLN. INFO.:			US 2001-300259P P	20010622
			WO 2002-IB2256 W	20020617

AB Solns. containing polymer/drug assemblies of a low-solubility drug and an amphiphilic polymer are disclosed. In addition, solid aggregated polymer/drug assemblies are disclosed comprising a low-solubility drug and polymer. For example, amorphous solid dispersions of the low-solubility drug 5-chloro-1H-indole-2-carboxylic acid [(1S)-benzyl-3-((3R,4S)-dihydroxypyrroldin-1-yl-)-(2R)-hydroxy-3-oxypropyl]amide and the amphiphilic polymer hydroxypropyl Me cellulose acetate succinate were prepared When no drug was present, small particles about 10-20 nm in size were present due to aggregation of the polymer (HPMCAS-MF) with itself, likely as a result of its amphiphilicity, which renders the polymer only sparingly water soluble For solns. containing drug solid dispersions, particles were present with an average size of about 80 nm. This demonstrates the formation of polymer/drug assemblies in solution

IT 146939-27-7, Ziprasidone 185021-64-1, Ziprasidone mesylate
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(compns. containing amphiphilic polymer and low-solubility drug assemblies)

L6 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 146939-27-7 CAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 185021-64-1 CAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S



CM 2

CRN 75-75-2
CMF C H4 O3 S

L6 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L6 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:573516 CAPLUS
DOCUMENT NUMBER: 133:168404
TITLE: Osmotic system for delivery of solid amorphous dispersions of drugs
INVENTOR(S): Appel, Leah Elizabeth; Curatolo, William John; Herbig, Scott Max; Nightingale, James Alan Schriver; Thombre, Avinash Govind
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 29 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1027888	A2	20000816	EP 2000-300572	20000126
EP 1027888	A3	20010228		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6706283	B1	20040316	US 2000-495061	20000131
CA 2298238	AA	20000810	CA 2000-2298238	20000209
CA 2298238	C	20051025		
JP 2000229846	A2	20000822	JP 2000-33132	20000210
BR 2000000358	A	20010821	BR 2000-358	20000210
US 2004175428	A1	20040909	US 2004-799536	20040311

PRIORITY APPLN. INFO.: US 1999-119406P P 19990210
US 2000-495061 A1 20000131

AB Controlled release dosage forms for low solubility drugs comprise an amorphous solid dispersion of the drug coated with a non-dissolving and non-eroding coating that controls the influx of water to the core so as to cause extrusion of a portion of the core, as well as a method of treating a disease or disorder comprising administering such dosage form to a person. A solid dispersion was prepared from [R-(R*,S*)]-5-chloro-N-[2-hydroxy-3-[methoxymethylamino-3-oxo-1-(phenylmethyl)propyl]propyl]-1H-indole-2-carboxamide (a glycogen phosphorylase inhibitor) and hydroxypropyl Me cellulose acetate succinate.

IT 146939-27-7, Ziprasidone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(osmotic system for delivery of solid amorphous dispersions of drugs)

RN 146939-27-7 CAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)

L6 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L6 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:573515 CAPLUS
DOCUMENT NUMBER: 133:182970
TITLE: Matrix controlled release device for a low-solubility drug
INVENTOR(S): Appel, Leah Elizabeth; Friesen, Dwayne Thomas; Curatolo, William John; Nightingale, James Alan Schriver; Thombre, Avinash Govind
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1027887	A2	20000816	EP 2000-300546	20000126
EP 1027887	A3	20010228		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2298245	C	20041130	CA 2000-2298245	20000209
JP 2000229888	A2	20000822	JP 2000-33446	20000210
BR 2000000359	A	20010814	BR 2000-359	20000210
JP 2005320354	A2	20051117	JP 2005-226695	20050804

PRIORITY APPLN. INFO.: US 1999-119400P P 19990210
JP 2000-33446 A3 20000210

AB Disclosed are a controlled release dosage form for a low solubility drug that is a spray-dried or spray-coated amorphous solid dispersion of the drug in an ionizable cellulosic polymer matrix that is in turn incorporated into a secondary erodible polymeric matrix and a method of treating a disease or disorder comprising administering such a dosage form. A batch of solid dispersion was prepared by spray-drying a solution containing drug 5-chloro-1H-indole-2-carboxylic acid [(1S-benzyl-3-(3R,4S)-dihydroxypyrrolidin-1-yl)-(2R)-hydroxy-3-oxypropyl]amide (water solubility 80 μg/mL) in acetone together with hydroxypropyl Me cellulose acetate succinate. The resulting solid dispersion was mixed with hydroxypropyl Me cellulose, lactose, and Mg stearate. The mixture was finally compressed to give tablets.

IT 146939-27-7, Ziprasidone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cellulosic polymer and pH-sensitive polymer matrixes for solid dispersion of low-solubility drugs)

RN 146939-27-7 CAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



```
=> s913329-18-7/rn
S913329-18-7 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s 913329-18-7/rn
             1 913329-18-7
             0 913329-18-7D
L7           1 913329-18-7/RN
                 (913329-18-7 (NOTL) 913329-18-7D )

=> d l7
```

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:1157390 CAPLUS
DN 145:449263
TI Use of metformin to counteract weight gain associated with aripiprazole or ziprasidone treatment
IN Cottingham, Elizabeth M.
PA Emc Research, LLC, USA
SO PCT Int. Appl., 17pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006116470	A1	20061102	WO 2006-US15764	20060425
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 2006246131	A1	20061102	US 2006-407231	20060419
PRAI	US 2005-675534P	P	20050428		
	US 2006-407231	A	20060419		

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> s 913329-18-7/rn full
             1 913329-18-7
             0 913329-18-7D
L8           1 913329-18-7/RN
                 (913329-18-7 (NOTL) 913329-18-7D )

=> d l7 hitstr
```

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
IT 913329-18-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(metformin to counteract weight gain associated with aripiprazole or ziprasidone treatment)
RN 913329-18-7 CAPLUS
CN Imidodicarbonimidic diamide, N,N-dimethyl-, monohydrochloride, mixt. with 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S



CM 2

CRN 1115-70-4
CMF C4 H11 N5 . Cl H



● HCl

```
=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   104.12     491.25

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -10.50     -10.50

FILE 'REGISTRY' ENTERED AT 19:30:39 ON 06 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     5 DEC 2006  HIGHEST RN 914910-45-5
DICTIONARY FILE UPDATES:    5 DEC 2006  HIGHEST RN 914910-45-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s ziprasidon?
L9          10 ZIPRASIDON?

=> d l9 1-10
```

L9 ANSWER 1 OF 10 REGISTRY COPYRIGHT 2006 ACS on STN
RN 864175-99-5 REGISTRY
ED Entered STN: 29 Sep 2005
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monohydrochloride, hydrate (2:1) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Ziprasidone hydrochloride hemihydrate
MF C21 H21 Cl N4 O S . Cl H . 1/2 H2 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (146939-27-7)



● HCl

● 1/2 H_2O

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 2 OF 10 REGISTRY COPYRIGHT 2006 ACS on STN
RN 199522-95-7 REGISTRY
ED Entered STN: 09 Jan 1998
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Ziprasidone tosylate
MF C21 H21 Cl N4 O S . C7 H8 O3 S
SR CA
LC STN Files: CA, CAPLUS, IMSPATENTS, IMSRESEARCH, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



4 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 3 OF 10 REGISTRY COPYRIGHT 2006 ACS on STN
RN 199191-69-0 REGISTRY
ED Entered STN: 31 Dec 1997
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monomethanesulfonate, trihydrate (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Ziprasidone mesylate hydrate
MF C21 H21 Cl N4 O S . C H4 O3 S . 3 H2 O
SR CA
LC STN Files: BIOTECHNO, CA, CAPLUS, CHEMCATS, EMBASE, IMSPATENTS, IMSRESEARCH, RTECS*, USAN, USPATFULL
(*File contains numerically searchable property data)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S



CM 2

CRN 75-75-2
CMF C H4 O3 S

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 4 OF 10 REGISTRY COPYRIGHT 2006 ACS on STN
RN 194280-91-6 REGISTRY
ED Entered STN: 19 Sep 1997
CN Piperazine, 1-[2-(6-chloro-2,3-dihydro-2-oxo-1H-indol-5-yl)ethyl]-4-[imino[2-(methylthio)phenyl]methyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN S-Methyldihydroziprasidone
MF C22 H25 Cl N4 O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 5 OF 10 REGISTRY COPYRIGHT 2006 ACS on STN
RN 188797-80-0 REGISTRY
ED Entered STN: 06 May 1997
CN 2H-Indol-2-one, 6-chloro-1,3-dihydro-5-[2-[4-(1-oxido-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Ziprasidone sulfoxide
MF C21 H21 Cl N4 O2 S
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 6 OF 10 REGISTRY COPYRIGHT 2006 ACS on STN
RN 188797-77-5 REGISTRY
ED Entered STN: 06 May 1997
CN 2H-Indol-2-one, 6-chloro-5-[2-[4-(1,1-dioxido-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-1,3-dihydro- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Ziprasidone sulfone
MF C21 H21 Cl N4 O3 S
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 7 OF 10 REGISTRY COPYRIGHT 2006 ACS on STN
RN 185021-64-1 REGISTRY
ED Entered STN: 15 Jan 1997
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monomethanesulfonate (9CI) (CA INDEX NAME)
OTHER NAMES:
CN CP 88059-27
CN Zeldox IM
CN Ziprasidone mesylate
MF C21 H21 Cl N4 O S . C H4 O3 S
CI COM
SR CAS Client Services
LC STN Files: BIOSIS, CA, CAPLUS, CHEMCATS, IMSPATENTS, IMSRESEARCH, IPA, PATDPASPC, PS, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S



CM 2

CRN 75-75-2
CMF C H4 O3 S

26 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
26 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 8 OF 10 REGISTRY COPYRIGHT 2006 ACS on STN
RN 146939-27-7 REGISTRY
ED Entered STN: 13 Apr 1993
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-[2-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one
CN 5-[2-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-2-indolinone
CN 5-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one
CN CP 88059
CN Geodon
CN Zaprasidone
CN Ziprasidone
MF C21 H21 Cl N4 O S
CI COM
SR World Health Organization (WHO)
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

563 REFERENCES IN FILE CA (1907 TO DATE)
10 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
566 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 9 OF 10 REGISTRY COPYRIGHT 2006 ACS on STN
RN 138982-67-9 REGISTRY
ED Entered STN: 14 Feb 1992
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monohydrochloride, monohydrate (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-[2-(4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl)ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride monohydrate
CN Ziprasidone hydrochloride monohydrate
CN Ziprasidone monohydrochloride monohydrate
MF C21 H21 Cl N4 O S . Cl H . H2 O
SR US Adopted Names Council (USAN)
LC STN Files: BIOTECHNO, CA, CAPLUS, CASREACT, CHEMCATS, EMBASE, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, PATDPASPC, PROUSDDR, PS, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
CRN (146939-27-7)

PAGE 1-A



● HCl

PAGE 2-A

● H_2O

14 REFERENCES IN FILE CA (1907 TO DATE)
14 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 10 OF 10 REGISTRY COPYRIGHT 2006 ACS on STN
RN 122883-93-6 REGISTRY
ED Entered STN: 29 Sep 1989
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-[2-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride
CN CP 88059-1
CN Zeldox
CN Ziprasidone hydrochloride
DR 152287-06-4, 118289-78-4
MF C21 H21 Cl N4 O S . Cl H
SR CA
LC STN Files: ADISINSIGHT, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CHEMCATS, CIN, EMBASE, IMSPATENTS, IMSRESEARCH, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
CRN (146939-27-7)



● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

61 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
61 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	24.64	515.89

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-10.50

FILE 'REGISTRY' ENTERED AT 19:31:40 ON 06 DEC 2006

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 DEC 2006 HIGHEST RN 914910-45-5
DICTIONARY FILE UPDATES: 5 DEC 2006 HIGHEST RN 914910-45-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> SET TERMSET E#

SET COMMAND COMPLETED

=> DEL SEL Y

=> SEL L9 10 RN

E1 THROUGH E1 ASSIGNED

=> S E1/RN

L10 1 122883-93-6/RN

=> SET TERMSET LOGIN

SET COMMAND COMPLETED

=> FIL CAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.52	516.41

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION

CA SUBSCRIBER PRICE 0.00 -10.50

FILE 'CAPLUS' ENTERED AT 19:31:44 ON 06 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 6 Dec 2006 VOL 145 ISS 24
FILE LAST UPDATED: 5 Dec 2006 (20061205/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

```
=>  S L10

L11         61 L10

=> s l11 and amorph?
        268712 AMORPH?
L12          4 L11 AND AMORPH?

=> d l12 1-4 ibib abs hitstr
```

L12 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1224322 CAPLUS
DOCUMENT NUMBER: 143:483095
TITLE: Preparation of amorphous ziprasidone hydrochloride
INVENTOR(S): Zetina-Rocha, Carlos; Rey, Allan W.; Buck, Matthew A.; Derdour, Lotfi; Horne, Stephen E.; Murthy, Keshava K. S.
PATENT ASSIGNEE(S): Apotex Pharmachem Inc., Can.
SOURCE: U.S. Pat. Appl. Publ., 6 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005256139	A1	20051117	US 2004-884991	20040707
CA 2467538	AA	20051114	CA 2004-2467538	20040514
WO 2005111032	A1	20051124	WO 2004-CA981	20040707

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: CA 2004-2467538 A 20040514
GI



I

AB The present invention relates to a new and useful amorphous form of ziprasidone hydrochloride (I). I amorphous form was prepared by treatment of the base in heptanes with HCl gas.

IT 122883-93-6P, Ziprasidone hydrochloride
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amorphous ziprasidone hydrochloride)

RN 122883-93-6 CAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

L12 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L12 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1154548 CAPLUS
DOCUMENT NUMBER: 143:427349
TITLE: Preparation of amorphous ziprasidone hydrochloride
INVENTOR(S): Tyagi, Om Dutt; Srivastava, Tushar Kumar; Chavan, Yuvraj Atmaram
PATENT ASSIGNEE(S): Lupin Limited, India
SOURCE: PCT Int. Appl., 10 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005100348	A1	20051027	WO 2005-IN115	20050415

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: IN 2004-MU450 A 20040415
GI



I

AB A process for preparation of ziprasidone hydrochloride (I) which is in amorphous form. The process comprises providing a I solution in a mixture of alc. solvent and acetonitrile and spray drying the solution of I.

IT 122883-93-6, Ziprasidone hydrochloride
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(preparation of amorphous ziprasidone hydrochloride)

RN 122883-93-6 CAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

L12 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:493702 CAPLUS
DOCUMENT NUMBER: 141:54361
TITLE: Polymorphic forms of ziprasidone and its hydrochloride
INVENTOR(S): Reddy, Manne Satyanarayana; Srinivasan, Thirumalai Rajan; Uppala, Venka Bhaskara Rao; Venkatesh, Mummadi; Prabhakar, Akundi Surya
PATENT ASSIGNEE(S): Reddy's Laboratories Limited, India; Reddy's Laboratories Inc.
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050655	A1	20040617	WO 2003-US38489	20031204
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003300814	A1	20040623	AU 2003-300814	20031204
US 2004152711	A1	20040805	US 2003-729837	20031204
PRIORITY APPLN. INFO.:			IN 2002-MA907 A	20021204
			WO 2003-US38489 W	20031204

AB The present invention is related to crystalline forms of ziprasidone and its hydrochloride salt and an amorphous form of ziprasidone hydrochloride and the process for the preparation thereof. The crystalline forms and amorphous form of the invention are suitable for pharmaceutical purposes in the treatment of psychosis. The processes of the invention are simple, non-hazardous and com. suitable. Thus, 50 g 5-(2-chloroethyl)-6-chlorooxindole, 47.5 g 3-(1-piperazinyl)-1,2-benzisothiazole and 500 mL cyclohexane were charged into an autoclave, followed by adding sodium carbonate 46, sodium iodide 3.2, and tetrabutylphosphonium bromide 14.8 g and the reaction mixture was maintained at 95-102° and 2.5 kg/cm2 till the reaction was completed, cooled to 300°, treated with 250 mL H2O, filtered to give, after washing with 100 mL water, the wet compound The wet compound was suspended in water, filtered, washed water, resuspended in acetone, filtered, washed with acetone, filtered, and dried at 60-65° to give 65.7 g ziprasidone base. Ziprasidone (5 g) and 50 mL acetic acid were placed into a round bottom flask and heated to 45-50°, treated slowly with 25 mL aqueous HCl over 20 min, refluxed, and treated with 10 mL water, followed by addition of 50 mL isopropanol. The reaction mass was cooled to 50°, followed by distilling off the solvent completely under vacuum., to give amorphous form of ziprasidone hydrochloride.

IT 122883-93-6P, Ziprasidone hydrochloride
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L12 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(prepn. of polymorphic forms of ziprasidone and its hydrochloride)
RN 122883-93-6 CAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:610236 CAPLUS
DOCUMENT NUMBER: 139:154927
TITLE: Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
INVENTOR(S): Perlman, Michael Ellis; Shanker, Ravi Mysore; Babcock, Walter Christian; Friesen, Dwayne Thomas; Rabenstein, Mark David; Smithey, Daniel Tod
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003063833	A1	20030807	WO 2003-IB335	20030128
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2474838	AA	20030807	CA 2003-2474838	20030128
EP 1469832	A1	20041027	EP 2003-700435	20030128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003007344	A	20041214	BR 2003-7344	20030128
JP 2005523262	T2	20050804	JP 2003-563527	20030128
US 2003228358	A1	20031211	US 2003-355747	20030131
PRIORITY APPLN. INFO.:			US 2002-354081P P	20020201
			WO 2003-IB335 W	20030128

AB A pharmaceutical composition comprises a solid amorphous dispersion comprising a low-solubility drug and a concentration-enhancing polymer and a lipophilic microphase-forming material. Alternatively, a solid amorphous dispersion comprising a low-solubility drug and a concentration-enhancing polymer is co-administered with a lipophilic microphase-forming material to an in vivo use environment. A spray solution was formed containing 2.5 wt% drug, 7.5 wt% HPMCAS-MF, and 90% acetone. The solution was spray-dried by directing a 2-fluid external-mix spray nozzle at 2.7 bar with a feed rate of 190 g/min into the stainless-steel chamber of a spray-dryer, by using nitrogen as the drying gas, maintained at a temperature of 137° at the inlet; the drying gas and evaporated solvent exited the drier at 49°. The resulting solid amorphous dispersion was collected and then dried in a solvent tray-drier by spreading the spray-dried particles onto polyethylene-lined trays to a depth of not more than 1 cm and then drying them at 40° for 25 h. After drying, dispersion 1 contained 25 wt% drug.

IT 122883-93-6, Ziprasidone hydrochloride
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. of amorphous dispersions of drugs and lipophilic microphase-forming materials)

RN 122883-93-6 CAPLUS

L12 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	32.05	548.46

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.00	-13.50

STN INTERNATIONAL LOGOFF AT 19:44:24 ON 06 DEC 2006

Connection closed by remote host

Connecting via Winsock to STN

NEWS 16	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 17	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 18	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 19	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS 20	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 21	NOV 13	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 22	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS 23	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 24	NOV 20	CA/CAplus patent kind codes will be updated
NEWS 25	DEC 01	CAS REGISTRY updated with new ambiguity codes

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

FILE COVERS 1907 - 10 Dec 2006 VOL 145 ISS 25
FILE LAST UPDATED: 8 Dec 2006 (20061208/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=>
Connection closed by remote host

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1625JXC

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 21:38:11 ON 10 DEC 2006
FILE 'CAPLUS' ENTERED AT 21:38:11 ON 10 DEC 2006
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.46	0.67

=> file reg

```
=> s 12883-93-6/rn
L1             0 12883-93-6/RN

=> s 122883-93-6/rn
L2             1 122883-93-6/RN

=> d l2
```

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 122883-93-6 REGISTRY
ED Entered STN: 29 Sep 1989
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-[2-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride
CN CP 88059-1
CN Zeldox
CN Ziprasidone hydrochloride
DR 152287-06-4, 118289-78-4
MF C21 H21 Cl N4 O S . Cl H
SR CA
LC STN Files: ADISINSIGHT, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CHEMCATS, CIN, EMBASE, IMSPATENTS, IMSRESEARCH, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
CRN (146939-27-7)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

61 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
61 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     3.66       4.33

FILE 'CAPLUS' ENTERED AT 21:40:42 ON 10 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 10 Dec 2006  VOL 145 ISS 25
FILE LAST UPDATED: 8 Dec 2006  (20061208/ED)
```



```
=> s l2 and ?morph?
            61 L2
       1149877 ?MORPH?
L3          10 L2 AND ?MORPH?

=> d l3 1-10 ibib abs hitstr
```

L3 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1313982 CAPLUS
DOCUMENT NUMBER: 144:57359
TITLE: Preparation of an anhydrate form of ziprasidone hydrochloride
INVENTOR(S): Zetina-Rocha, Carlos; Rey, Allan W.; Horne, Stephen E.
PATENT ASSIGNEE(S): Apotex Pharmachem Inc., Can.
SOURCE: U.S. Pat. Appl. Publ., 4 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005277651	A1	20051215	US 2004-928139	20040830
US 7087611	B2	20060808		
CA 2471219	AA	20051214	CA 2004-2471219	20040614
PRIORITY APPLN. INFO.:			CA 2004-2471219 A	20040614

GI



I

AB The anhydrate form of ziprasidone-HCl (I) was prepared from the base in EtOH with addition of HCl in isopropanol.
IT 122883-93-6P, Ziprasidone hydrochloride
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of an anhydrate form of ziprasidone hydrochloride)
RN 122883-93-6 CAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1224322 CAPLUS
DOCUMENT NUMBER: 143:483095
TITLE: Preparation of amorphous ziprasidone hydrochloride
INVENTOR(S): Zetina-Rocha, Carlos; Rey, Allan W.; Buck, Matthew A.; Derdour, Lotfi; Horne, Stephen E.; Murthy, Keshava K. S.
PATENT ASSIGNEE(S): Apotex Pharmachem Inc., Can.
SOURCE: U.S. Pat. Appl. Publ., 6 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005256139	A1	20051117	US 2004-884991	20040707
CA 2467538	AA	20051114	CA 2004-2467538	20040514
WO 2005111032	A1	20051124	WO 2004-CA981	20040707
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			CA 2004-2467538 A	20040514

GI



I

AB The present invention relates to a new and useful amorphous form of ziprasidone hydrochloride (I). I amorphous form was prepared by treatment of the base in heptanes with HCl gas.
IT 122883-93-6P, Ziprasidone hydrochloride
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amorphous ziprasidone hydrochloride)
RN 122883-93-6 CAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L3 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1216406 CAPLUS
DOCUMENT NUMBER: 143:466204
TITLE: Preparation of a ziprasidone hydrochloride polymorph
INVENTOR(S): Ventimiglia, Gianpiero; Allegrini, Pietro; Castaldi, Graziano
PATENT ASSIGNEE(S): Dipharma S.p.A., Italy; Lundbeck Pharmaceuticals Italy S.p.A.
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005108395	A1	20051117	WO 2005-EP52091	20050510

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: IT 2004-MI944 A 20040511

AB A new crystalline form of ziprasidone-HCl hemihydrate, a process for its preparation, its use for the purification of ziprasidone, its pharmaceutical compns. and their use in therapy are disclosed.

IT 122883-93-6, Ziprasidone hydrochloride
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of ziprasidone hydrochloride polymorph)
RN 122883-93-6 CAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1154548 CAPLUS
DOCUMENT NUMBER: 143:427349
TITLE: Preparation of amorphous ziprasidone hydrochloride
INVENTOR(S): Tyagi, Om Dutt; Srivastava, Tushar Kumar; Chavan, Yuvraj Atmaram
PATENT ASSIGNEE(S): Lupin Limited, India
SOURCE: PCT Int. Appl., 10 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005100348	A1	20051027	WO 2005-IN115	20050415

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: IN 2004-MU450 A 20040415

GI



I

AB A process for preparation of ziprasidone hydrochloride (I) which is in amorphous form. The process comprises providing a I solution in a mixture of alc. solvent and acetonitrile and spray drying the solution of I.

IT 122883-93-6, Ziprasidone hydrochloride
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(preparation of amorphous ziprasidone hydrochloride)
RN 122883-93-6 CAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:588956 CAPLUS
DOCUMENT NUMBER: 143:103263
TITLE: Process for the preparation of the polymorphic crystalline form B2 of ziprasidone base
INVENTOR(S): Aronhime, Judith; Mendelovici, Marioara; Koltai, Tamas; Moshkovits-Kapstan, Rinat; Nidam, Tamar
PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061493	A2	20050707	WO 2004-US43127	20041220
WO 2005061493	A3	20050909		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2550485	AA	20050707	CA 2004-2550485	20041220
US 2005197347	A1	20050908	US 2004-18489	20041220
EP 1592688	A2	20051109	EP 2004-815237	20041220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				

PRIORITY APPLN. INFO.: US 2003-531244P P 20031218
WO 2004-US43127 W 20041220

AB A process for the preparation of the polymorphic crystalline form B2 of 5-[2-[4-(3,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one (ziprasidone base) is presented. Processes for preparing pharmaceutically acceptable salts, particularly ziprasidone hydrochlorides and mesyl salts, are also presented.

IT 122883-93-6, Ziprasidone hydrochloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of polymorphic crystalline form B2 of ziprasidone base)

RN 122883-93-6 CAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

L3 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L3 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:160836 CAPLUS
DOCUMENT NUMBER: 142:225693
TITLE: Polymorphic forms of ziprasidone HCl and processes for their preparation
INVENTOR(S): Koltai, Tamas; Hedvati, Lilach; Mendelovici, Marioara; Nidam, Tamar
PATENT ASSIGNEE(S): Israel
SOURCE: U.S. Pat. Appl. Publ., 38 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005043324	A1	20050224	US 2004-860926	20040603
US 2005059680	A1	20050317	US 2004-860864	20040603
CA 2528100	AA	20050421	CA 2004-2528100	20040603
WO 2005035531	A1	20050421	WO 2004-US18018	20040603
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1546146	A1	20050629	EP 2004-754586	20040603
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				

PRIORITY APPLN. INFO.: US 2003-475806P P 20030603
US 2003-487913P P 20030716
US 2003-494970P P 20030813
US 2003-528346P P 20031209
US 2004-571997P P 20040517
WO 2004-US18018 W 20040603

AB Provided are various polymorphic forms of ziprasidone HCl and processes for their preparation The crystalline form of ziprasidone HCl is characterized by a powder X-ray diffraction pattern. The present invention provides a process for preparing ziprasidone HCl Form E, comprising
combining aqueous HCl with ziprasidone base in the presence of Et acetate or acetonitrile to obtain a slurry; maintaining the slurry to obtain ziprasidone HCl; and recovering the ziprasidone HCl.

IT 122883-93-6P, Ziprasidone hydrochloride
RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation)
(polymorphic forms of ziprasidone HCl and processes for their preparation)

RN 122883-93-6 CAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L3 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:158530 CAPLUS
DOCUMENT NUMBER: 142:246075
TITLE: Crystalline ziprasidone HCl
INVENTOR(S): Mendelovici, Marioara; Koltai, Tamas; Aronhime, Judith; Balanov, Anna; Gome, Boaz; Shenkar, Natalia; Amir, Ehud
PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals Usa, Inc.
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016325	A2	20050224	WO 2004-US18017	20040603
WO 2005016325	A3	20050324		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2528192	AA	20050224	CA 2004-2528192	20040603
US 2005059680	A1	20050317	US 2004-860864	20040603
CA 2528100	AA	20050421	CA 2004-2528100	20040603
WO 2005035531	A1	20050421	WO 2004-US18018	20040603
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1530570	A2	20050518	EP 2004-754585	20040603
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
EP 1546146	A1	20050629	EP 2004-754586	20040603
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				

PRIORITY APPLN. INFO.:

US 2003-475806P	P	20030603
US 2003-487913P	P	20030716
US 2003-494970P	P	20030813
US 2003-528346P	P	20031209
US 2004-571997P	P	20040517
WO 2004-US18017	W	20040603
WO 2004-US18018	W	20040603

GI

L3 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I

AB Provided are crystalline ziprasidone (I)-HCl and processes for its preparation
Crystal forms of I-HCl were prepared from solvents such as toluene, chlorobenzene-methanol, di-Et carbonate, acetonitrile, and others.
IT 122883-93-6, Ziprasidone hydrochloride
RL: FMU (Formation, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); FORM (Formation, nonpreparative); PROC (Process)
(crystalline forms of ziprasidone HCl)
RN 122883-93-6 CAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L3 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:493702 CAPLUS
DOCUMENT NUMBER: 141:54361
TITLE: Polymorphic forms of ziprasidone and its hydrochloride
INVENTOR(S): Reddy, Manne Satyanarayana; Srinivasan, Thirumalai Rajan; Uppala, Venka Bhaskara Rao; Venkatesh, Mummadi; Prabhakar, Akundi Surya
PATENT ASSIGNEE(S): Reddy's Laboratories Limited, India; Reddy's Laboratories Inc.
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050655	A1	20040617	WO 2003-US38489	20031204
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003300814	A1	20040623	AU 2003-300814	20031204
US 2004152711	A1	20040805	US 2003-729837	20031204

PRIORITY APPLN. INFO.:

IN 2002-MA907	A	20021204
WO 2003-US38489	W	20031204

AB The present invention is related to crystalline forms of ziprasidone and its hydrochloride salt and an amorphous form of ziprasidone hydrochloride and the process for the preparation thereof. The crystalline forms and amorphous form of the invention are suitable for pharmaceutical purposes in the treatment of psychosis. The processes of the invention are simple, non-hazardous and com. suitable. Thus, 50 g 5-(2-chloroethyl)-6-chlorooxindole, 47.5 g 3-(1-piperazinyl)-1,2-benzisothiazole and 500 mL cyclohexane were charged into an autoclave, followed by adding sodium carbonate 46, sodium iodide 3.2, and tetrabutylphosphonium bromide 14.8 g and the reaction mixture was maintained at 95-102° and 2.5 kg/cm2 till the reaction was completed, cooled to 300°, treated with 250 mL H2O, filtered to give, after washing with 100 mL water, the wet compound The wet compound was suspended in water, filtered, washed water, resuspended in acetone, filtered, washed with acetone, filtered, and dried at 60-65° to give 65.7 g ziprasidone base. Ziprasidone (5 g) and 50 mL acetic acid were placed into a round bottom flask and heated to 45-50°, treated slowly with 25 mL aqueous HCl over 20 min, refluxed, and treated with 10 mL water, followed by addition of 50 mL isopropanol. The reaction mass was cooled to 50°, followed by distilling off the solvent completely under vacuum., to give amorphous form of ziprasidone hydrochloride.
IT 122883-93-6P, Ziprasidone hydrochloride
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

L3 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(Uses)
(prepn. of polymorphic forms of ziprasidone and its hydrochloride)
RN 122883-93-6 CAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:610236 CAPLUS
DOCUMENT NUMBER: 139:154927
TITLE: Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
INVENTOR(S): Perlman, Michael Ellis; Shanker, Ravi Mysore; Babcock, Walter Christian; Friesen, Dwayne Thomas; Rabenstein, Mark David; Smithey, Daniel Tod
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003063833	A1	20030807	WO 2003-IB335	20030128
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2474838	AA	20030807	CA 2003-2474838	20030128
EP 1469832	A1	20041027	EP 2003-700435	20030128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003007344	A	20041214	BR 2003-7344	20030128
JP 2005523262	T2	20050804	JP 2003-563527	20030128
US 2003228358	A1	20031211	US 2003-355747	20030131

PRIORITY APPLN. INFO.: US 2002-354081P P 20020201
WO 2003-IB335 W 20030128

AB A pharmaceutical composition comprises a solid amorphous dispersion comprising a low-solubility drug and a concentration-enhancing polymer and a lipophilic microphase-forming material. Alternatively, a solid amorphous dispersion comprising a low-solubility drug and a concentration-enhancing polymer is co-administered with a lipophilic microphase-forming material to an in vivo use environment. A spray solution was formed containing 2.5 wt% drug, 7.5 wt% HPMCAS-MF, and 90% acetone. The solution was spray-dried by directing a 2-fluid external-mix spray nozzle at 2.7 bar with a feed rate of 190 g/min into the stainless-steel chamber of a spray-dryer, by using nitrogen as the drying gas, maintained at a temperature of 137° at the inlet; the drying gas and evaporated solvent exited the drier at 49°. The resulting solid amorphous dispersion was collected and then dried in a solvent tray-drier by spreading the spray-dried particles onto polyethylene-lined trays to a depth of not more than 1 cm and then drying them at 40° for 25 h. After drying, dispersion 1 contained 25 wt% drug.

IT 122883-93-6, Ziprasidone hydrochloride
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. of amorphous dispersions of drugs and lipophilic microphase-forming materials)

RN 122883-93-6 CAPLUS

L3 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:355752 CAPLUS
DOCUMENT NUMBER: 131:719
TITLE: A covalent conjugate of clozapine with a fatty acid and its use for treating schizophrenia
INVENTOR(S): Bradley, Matthews O.; Shashoua, Victor E.; Swindell, Charles S.; Webb, Nigel L.
PATENT ASSIGNEE(S): Neuromedica, Inc., USA
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9926661	A1	19990603	WO 1998-US24412	19981116
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6197764	B1	20010306	US 1997-978541	19971126
CA 2310850	AA	19990603	CA 1998-2310850	19981116
AU 9914115	A1	19990615	AU 1999-14115	19981116
AU 746472	B2	20020502		
EP 1044023	A1	20001018	EP 1998-957987	19981116
EP 1044023	B1	20050525		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE, IE				
JP 2001523732	T2	20011127	JP 2000-521862	19981116
AT 296116	E	20050615	AT 1998-957987	19981116
ES 2244098	T3	20051201	ES 1998-957987	19981116

PRIORITY APPLN. INFO.: US 1997-978541 A 19971126
WO 1998-US24412 W 19981116

AB The invention provides compns. that include conjugates of a fatty acid mol., preferably cis-docosahexaenoic acid, and clozapine. The conjugates are useful in treating psychol. disorders such as schizophrenia. Docosahexaenoic acid-clozapine (preparation given) was at least six times longer-acting than clozapine against locomotor behavioral arousal in rats treated with R(-) apomorphine.

IT 122883-93-6, Ziprasidone hydrochloride
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical further containing; clozapine conjugate with fatty acid for treating schizophrenia)

RN 122883-93-6 CAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

L3 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT